SI1740569T1 - Imidazolni derivati kot inhibitorji TAFIa - Google Patents

Imidazolni derivati kot inhibitorji TAFIa

Info

Publication number
SI1740569T1
SI1740569T1 SI200530185T SI200530185T SI1740569T1 SI 1740569 T1 SI1740569 T1 SI 1740569T1 SI 200530185 T SI200530185 T SI 200530185T SI 200530185 T SI200530185 T SI 200530185T SI 1740569 T1 SI1740569 T1 SI 1740569T1
Authority
SI
Slovenia
Prior art keywords
imidazole derivatives
derivatives used
tafia inhibitors
tafia
inhibitors
Prior art date
Application number
SI200530185T
Other languages
English (en)
Slovenian (sl)
Inventor
Christopher Kallus
Holger Heitsch
Andreas Lindenschmidt
Sven Grueneberg
Hauke Szillat
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1740569(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of SI1740569T1 publication Critical patent/SI1740569T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200530185T 2004-04-22 2005-04-07 Imidazolni derivati kot inhibitorji TAFIa SI1740569T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
EP05731221A EP1740569B1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (1)

Publication Number Publication Date
SI1740569T1 true SI1740569T1 (sl) 2008-06-30

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530185T SI1740569T1 (sl) 2004-04-22 2005-04-07 Imidazolni derivati kot inhibitorji TAFIa

Country Status (34)

Country Link
EP (2) EP1864979B1 (cg-RX-API-DMAC10.html)
JP (1) JP4939401B2 (cg-RX-API-DMAC10.html)
KR (1) KR101162047B1 (cg-RX-API-DMAC10.html)
CN (1) CN100572376C (cg-RX-API-DMAC10.html)
AR (1) AR053302A1 (cg-RX-API-DMAC10.html)
AT (2) ATE523505T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005238144B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0510159A (cg-RX-API-DMAC10.html)
CA (1) CA2563401C (cg-RX-API-DMAC10.html)
CR (1) CR8650A (cg-RX-API-DMAC10.html)
CY (1) CY1108087T1 (cg-RX-API-DMAC10.html)
DE (2) DE102004020186A1 (cg-RX-API-DMAC10.html)
DK (1) DK1740569T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP066941A (cg-RX-API-DMAC10.html)
ES (1) ES2299026T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20080099T3 (cg-RX-API-DMAC10.html)
IL (1) IL178672A (cg-RX-API-DMAC10.html)
MA (1) MA28543B1 (cg-RX-API-DMAC10.html)
MY (1) MY140903A (cg-RX-API-DMAC10.html)
NI (1) NI200600217A (cg-RX-API-DMAC10.html)
NO (1) NO20065320L (cg-RX-API-DMAC10.html)
NZ (1) NZ550757A (cg-RX-API-DMAC10.html)
PE (1) PE20060172A1 (cg-RX-API-DMAC10.html)
PL (1) PL1740569T3 (cg-RX-API-DMAC10.html)
PT (1) PT1740569E (cg-RX-API-DMAC10.html)
RS (1) RS50553B (cg-RX-API-DMAC10.html)
RU (1) RU2375356C2 (cg-RX-API-DMAC10.html)
SI (1) SI1740569T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN06341A1 (cg-RX-API-DMAC10.html)
TW (1) TWI359016B (cg-RX-API-DMAC10.html)
UA (1) UA87306C2 (cg-RX-API-DMAC10.html)
UY (1) UY28868A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005105781A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200607668B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
MX2010012793A (es) * 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
AU2009310841A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
US8865906B2 (en) * 2009-05-15 2014-10-21 Sanofi Process for the preparation of a compound useful as an inhibitor of TAFIa
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
SG10201502026XA (en) 2010-03-18 2015-05-28 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
WO2012062730A1 (en) 2010-11-11 2012-05-18 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
EP2782576B1 (en) * 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012338A3 (cs) * 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
CA2472239A1 (en) 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
UY28868A1 (es) 2005-11-30
UA87306C2 (en) 2009-07-10
TW200602325A (en) 2006-01-16
ZA200607668B (en) 2008-03-26
KR20070007346A (ko) 2007-01-15
PT1740569E (pt) 2008-03-31
ES2299026T3 (es) 2008-05-16
CR8650A (es) 2007-12-04
RS50553B (sr) 2010-05-07
HK1101823A1 (zh) 2007-10-26
NZ550757A (en) 2010-06-25
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
DE102004020186A1 (de) 2005-11-17
HRP20080099T3 (en) 2008-03-31
EP1740569A1 (de) 2007-01-10
JP2007533672A (ja) 2007-11-22
EP1864979A1 (de) 2007-12-12
IL178672A (en) 2011-08-31
BRPI0510159A (pt) 2007-10-02
PL1740569T3 (pl) 2008-07-31
TNSN06341A1 (en) 2008-02-22
KR101162047B1 (ko) 2012-07-04
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
PE20060172A1 (es) 2006-03-31
MA28543B1 (fr) 2007-04-03
RU2375356C2 (ru) 2009-12-10
AU2005238144B2 (en) 2010-08-26
EP1740569B1 (de) 2008-02-20
NI200600217A (es) 2008-06-17
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
CY1108087T1 (el) 2014-02-12
AR053302A1 (es) 2007-05-02
IL178672A0 (en) 2007-02-11
TWI359016B (en) 2012-03-01
WO2005105781A1 (de) 2005-11-10
EP1864979B1 (de) 2011-09-07
RU2006141246A (ru) 2008-06-10
NO20065320L (no) 2007-01-12
ATE386737T1 (de) 2008-03-15
DK1740569T3 (da) 2008-06-02
CA2563401C (en) 2012-08-07
DE502005002927D1 (de) 2008-04-03
MY140903A (en) 2010-01-29
ATE523505T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL194582A0 (en) Condensed imidazole derivatives as aromatase inhibitors
ZA200903286B (en) Hydantoin derivatives used as MMP Inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
IL193482A0 (en) Hydantoin based kinase inhibitors
IL178672A0 (en) Imidazole derivatives used as tafia inhibitors
ZA200610771B (en) Quinazolinedolone derivatives as PARP inhibitors
IL197955A0 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
IL189194A0 (en) Substituted benzimidazoles as kinase inhibitors
ZA200705075B (en) Novel hydantoin derivatives as metalloproteinase inhibitors
ZA200904175B (en) Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
ZA200705076B (en) Novel hydantoin derivatives as metalloproteinase inhibitors
ZA200705068B (en) Hydantoin derivatives useful as metalloproteinase inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
PL1912972T3 (pl) Podstawione związki imidazolowe jako inhibitory KSP
PL2104497T3 (pl) Pochodne sulfamidu jako inhibitory TAFIa
ZA200607198B (en) Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors
IL184559A0 (en) Imidazole derivatives
PT1937673E (pt) Derivados de imidazol como derivados do tafi-a
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
ZA200806993B (en) Hydantoin based kinase inhibitors
HK1122805A (en) Condensed imidazole derivatives as aromatase inhibitors